T. Rowe Price Associates
IMNM icon

T. Rowe Price Associates’s Immunome IMNM Stock Holding History

T. Rowe Price Associates’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.6M Sell
1,773,229
-1,085,634
-38% -$23.2M ﹤0.01% 970
2026
Q1 		$62.5M Sell
2,858,863
-521,377
-15% -$11.6M 0.01% 717
2025
Q4 		$72.6M Sell
3,380,240
-362,530
-10% -$6.36M 0.01% 703
2025
Q3 		$43.8M Buy
3,742,770
+760,690
+26% +$7.57M ﹤0.01% 844
2025
Q2 		$27.7M Sell
2,982,080
-87,527
-3% -$718K ﹤0.01% 886
2025
Q1 		$20.7M Buy
3,069,607
+786,853
+34% +$7.55M ﹤0.01% 945
2024
Q4 		$24.2M Buy
2,282,754
+246,447
+12% +$2.98M ﹤0.01% 948
2024
Q3 		$29.8M Buy
2,036,307
+15,188
+0.8% +$216K ﹤0.01% 896
2024
Q2 		$24.5M Sell
2,021,119
-224,554
-10% -$3.51M ﹤0.01% 905
2024
Q1 		$55.4M Buy
2,245,673
+1,194,451
+114% +$24.2M 0.01% 706
2023
Q4 		$11.2M Buy
1,051,222
+877,592
+505% +$7.3M ﹤0.01% 1073
2023
Q3 		$1.45M Buy
+173,630
New +$1.28M ﹤0.01% 1619
2021
Q4 		– Sell
-10,800
Closed -$263K – 3012
2021
Q3 		$263K Buy
+10,800
New +$188K ﹤0.01% 2623

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

T. Rowe Price Associates's IMNM Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Immunome (IMNM) stake by 38% in Q2 2026, selling an estimated $23.2M and leaving 1,773,229 shares worth $37.6M. The position accounts for ﹤0.01% of the portfolio, ranked #970.

T. Rowe Price Associates first reported a position in IMNM in Q3 2021 and has held it in 13 quarters since. The position peaked at $72.6M in Q4 2025. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • T. Rowe Price Associates held 1,773,229 shares of Immunome worth $37.6M as of Q2 2026.
  • T. Rowe Price Associates sold 1,085,634 Immunome shares in Q2 2026, an estimated $23.2M.
  • Immunome made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #970 holding.
  • T. Rowe Price Associates first reported a position in Immunome in Q3 2021 and has held it in 13 quarters since.
  • T. Rowe Price Associates's Immunome position peaked at $72.6M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.